WuXi Biologics CEO joins ISPE Board

Dr Chris Chen is the first board member to join ISPE board of directors from Asia

Dr Chris Chen, WuXi Biologics CEO, has been appointed by International Society for Pharmaceutical Engineering (ISPE) to serve on the International Board of Directors for a two-year term. Chen is also the first board member from Asia.

Boasting 18,500 members, ISPE is the world’s largest not-for-profit association serving its members by leading scientific, technical and regulatory advancement throughout the entire pharmaceutical lifecycle.

In March 2014, WuXi Biologics’ drug substance facility received the Honorable Mention Award “Facility-of-the-Year” from ISPE, a first for China.

“ISPE strives to improve manufacturing of quality medicines for global patients. I’m honoured and proud to be part of ISPE’s Board to engage in the governance and strategic direction of the Society, which is a great opportunity for me personally as well as WuXi Biologics,” said Dr Chen.

ISPE keynote speaker

On November 4, 2018, ISPE Annual Meeting was held in Philadelphia, Pennsylvania (US), where members who had been elected to serve on the new board formally took office.

Dr Chris Chen gave a keynote speech of “Biomanufacturing Facilities of the Future: the WuXi Biologics Story”.

During the speech, Dr Chen highlighted the pioneering scale-out strategy using disposable bioreactors to produce biologics at commercial scale and WuXi Biologics’ investment in developing continuous biomanufacturing process to reduce manufacturing cost and ensure affordability.

Other keynote speakers included Lars Fruergaard Jorgensen, President and CEO of Novo Nordisk; Kevin Nepveux, Vice President of Pfizer Global Supply; Becky Furuta, Team Novo Nordisk Diabetes Cycling Team and Health Care Policy Consultant; and Nick Leschly, CEO of Bulebird Bio.

More than 1500 professionals from 28 countries including regulators from 14 countries such as the US FDA attended the event.

Companies